Drug intelligence / Profile preview

moxifloxacin + dexamethasone

Development stage
Phase 3
Lead developer
Alcon
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

Moxifloxacin + dexamethasone is a fixed-dose combination ophthalmic medication used primarily for the treatment of bacterial eye infections and associated inflammation. It combines moxifloxacin, a fourth-generation fluoroquinolone antibiotic, with dexamethasone, a potent synthetic glucocorticoid corticosteroid. Moxifloxacin acts by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair in bacteria. This results in bactericidal activity against a broad spectrum of Gram-positive and Gram-negative organisms[6][8]. Dexamethasone exerts anti-inflammatory effects by binding to the glucocorticoid receptor and modulating gene expression to suppress pro-inflammatory mediators such as prostaglandins[3][6]. The combination is indicated for use in ocular conditions where both infection and inflammation are present or suspected[5].

Brand names
MoxigramMilflodexMyticomVigadexaApdrops DMMosi-DFMoxiblu-DMoxicip DMflotas DXMoxoft D
Other names
moxifloxacin + dexamethasone
02

Targets

Topo IV (Bacterial Topoisomerase IV)GR (Glucocorticoid receptor)DNA gyrase

Beyond the preview

Go deeper on moxifloxacin + dexamethasone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on moxifloxacin + dexamethasone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call